383 results on '"Strunk, Tobias"'
Search Results
102. Responsiveness of human monocytes to the commensal bacterium Staphylococcus epidermidis develops late in gestation
- Author
-
Strunk, Tobias, primary, Prosser, Amy, additional, Levy, Ofer, additional, Philbin, Victoria, additional, Simmer, Karen, additional, Doherty, Dorota, additional, Charles, Adrian, additional, Richmond, Peter, additional, Burgner, David, additional, and Currie, Andrew, additional
- Published
- 2012
- Full Text
- View/download PDF
103. Histologic Chorioamnionitis Is Associated With Reduced Risk of Late-Onset Sepsis in Preterm Infants
- Author
-
Strunk, Tobias, primary, Doherty, Dorota, additional, Jacques MBiostat, Angela, additional, Simmer, Karen, additional, Richmond, Peter, additional, Kohan, Rolland, additional, Charles, Adrian, additional, and Burgner, David, additional
- Published
- 2012
- Full Text
- View/download PDF
104. Preterm Infants Have Deficient Monocyte and Lymphocyte Cytokine Responses to Group B Streptococcus
- Author
-
Currie, Andrew J., primary, Curtis, Samantha, additional, Strunk, Tobias, additional, Riley, Karen, additional, Liyanage, Khemanganee, additional, Prescott, Susan, additional, Doherty, Dorota, additional, Simmer, Karen, additional, Richmond, Peter, additional, and Burgner, David, additional
- Published
- 2011
- Full Text
- View/download PDF
105. Method of bacterial killing differentially affects the human innate immune response to Staphylococcus epidermidis
- Author
-
Strunk, Tobias, primary, Richmond, Peter, additional, Prosser, Amy, additional, Simmer, Karen, additional, Levy, Ofer, additional, Burgner, David, additional, and Currie, Andrew, additional
- Published
- 2010
- Full Text
- View/download PDF
106. Innate immunity in human newborn infants: prematurity means more than immaturity
- Author
-
Strunk, Tobias, primary, Currie, Andrew, additional, Richmond, Peter, additional, Simmer, Karen, additional, and Burgner, David, additional
- Published
- 2010
- Full Text
- View/download PDF
107. TLR2 Mediates Recognition of Live Staphylococcus epidermidis and Clearance of Bacteremia
- Author
-
Strunk, Tobias, primary, Power Coombs, Melanie R., additional, Currie, Andrew J., additional, Richmond, Peter, additional, Golenbock, Douglas T., additional, Stoler-Barak, Liat, additional, Gallington, Leighanne C., additional, Otto, Michael, additional, Burgner, David, additional, and Levy, Ofer, additional
- Published
- 2010
- Full Text
- View/download PDF
108. Erythropoietin inhibits cytokine production of neonatal and adult leukocytes
- Author
-
Strunk, Tobias, primary, Härtel, Christoph, additional, Temming, Petra, additional, Matzke, Nadja, additional, Zimmer, Janna, additional, and Schultz, Christian, additional
- Published
- 2007
- Full Text
- View/download PDF
109. Rhodococcus equi Meningitis After Ventriculoperitoneal Shunt Insertion in a Preterm Infant
- Author
-
Strunk, Tobias, primary, Gardiner, Katharine, additional, Simmer, Karen, additional, Atlas, David, additional, and Keil, Anthony D., additional
- Published
- 2007
- Full Text
- View/download PDF
110. Neonatal immune responses to coagulase-negative staphylococci
- Author
-
Strunk, Tobias, primary, Richmond, Peter, additional, Simmer, Karen, additional, Currie, Andrew, additional, Levy, Ofer, additional, and Burgner, David, additional
- Published
- 2007
- Full Text
- View/download PDF
111. Genetic susceptibility to neonatal infection
- Author
-
Strunk, Tobias, primary and Burgner, David, additional
- Published
- 2006
- Full Text
- View/download PDF
112. A young girl's swollen nipple
- Author
-
Strunk, Tobias, primary, Schultz, Christian, additional, and Merz, Hartmut, additional
- Published
- 2005
- Full Text
- View/download PDF
113. Differential Maturation of the Innate Immune Response in Human Fetuses
- Author
-
Strunk, Tobias, primary, Temming, Petra, additional, Gembruch, Ulrich, additional, Reiss, Irwin, additional, Bucsky, Peter, additional, and Schultz, Christian, additional
- Published
- 2004
- Full Text
- View/download PDF
114. Human alkaline phosphatase dephosphorylates microbial products and is elevated in preterm neonates with a history of late-onset sepsis
- Author
-
Pettengill, Matthew, Matute, Juan D., Tresenriter, Megan, Hibbert, Julie, Burgner, David, Richmond, Peter, Luis Millán, José, Ozonoff, Al, Strunk, Tobias, Currie, Andrew, and Levy, Ofer
- Subjects
Biology and Life Sciences ,Anatomy ,Body Fluids ,Blood ,Blood Plasma ,Medicine and Health Sciences ,Physiology ,Immunology ,Immune Response ,Inflammation ,Diagnostic Medicine ,Signs and Symptoms ,Pathology and Laboratory Medicine ,Sepsis ,Digestive System ,Gastrointestinal Tract ,Immune System Proteins ,Immune Receptors ,Toll-like Receptors ,Biochemistry ,Proteins ,Cell Biology ,Signal Transduction ,Physical Sciences ,Chemistry ,Chemical Compounds ,Phosphates ,Developmental Biology ,Neonates ,Neonatal Sepsis - Abstract
Background: A host defense function for Alkaline phosphatases (ALPs) is suggested by the contribution of intestinal ALP to detoxifying bacterial lipopolysaccharide (endotoxin) in animal models in vivo and the elevation of ALP activity following treatment of human cells with inflammatory stimuli in vitro. However the activity of ALP in human plasma (primarily tissue-nonspecific ALP; TNAP) on lipopolysaccharide and other microbial products has not been assessed, nor has its expression been studied in preterm newborns, a vulnerable population at high risk of sepsis. In this context, the aim of our study was to characterize the activity of TNAP on Toll-like receptor (TLR) agonists and assess the concentrations of plasma ALP during late-onset sepsis in preterm newborns. Methods: Recombinant human TNAP was incubated with microbial products and phosphate release was measured by malachite green assay. Plasma ALP activity was measured serially in a cohort of preterm (N = 129) infants at high risk of late-onset sepsis (LOS). Results: TNAP dephosphorylates poly-inosine:cytosine (Toll-like receptor (TLR) 3 agonist) and LPS from Klebsiella pneumoniae and Salmonella minnesota (TLR4 agonists). Plasma ALP significantly increased postnatally over the first 4 weeks of life in preterm and term newborns. Bacteremic LOS in preterm infants (gestational age ≤ 30 weeks) was associated with significantly elevated plasma ALP at 4 weeks postnatal age. Conclusions: TNAP, the main circulating isozyme of ALP, de-phosphorylates TLR agonists, demonstrates a post-natal age dependent increase in preterm and term plasma across the first 4 weeks of life, and is elevated in association with preterm LOS.
- Published
- 2017
- Full Text
- View/download PDF
115. Anaplastic ependymoma with pleuropulmonary relapse
- Author
-
Strunk, Tobias, primary, Schultz, Christian, additional, Gottschalk, Stefan, additional, Reusche, Erich, additional, and Bucsky, Peter, additional
- Published
- 2003
- Full Text
- View/download PDF
116. Subacute leukencephalopathy after low-dose intrathecal methotrexate in an adolescent heterozygous for the MTHFR C677T polymorphism
- Author
-
Strunk, Tobias, primary, Gottschalk, Stefan, additional, Goepel, Wolfgang, additional, Bucsky, Peter, additional, and Schultz, Christian, additional
- Published
- 2002
- Full Text
- View/download PDF
117. Polyclonal intravenous immunoglobulin to prevent brain injury in preterm infants
- Author
-
Schultz, Christian, primary, Temming, Petra, additional, Gembruch, Ulrich, additional, Strunk, Tobias, additional, and Bucsky, Peter, additional
- Published
- 2002
- Full Text
- View/download PDF
118. Increased numbers of CCR5+ interferon-?- and tumor necrosis factor-?-secreting T lymphocytes in multiple sclerosis patients
- Author
-
Strunk, Tobias, primary, Bubel, Stefanie, additional, Mascher, Beate, additional, Schlenke, Peter, additional, Kirchner, Holger, additional, and Wandinger, Klaus-Peter, additional
- Published
- 2000
- Full Text
- View/download PDF
119. Increased numbers of CCR5 interferon‐γ– and tumor necrosis factor‐α–secreting T lymphocytes in multiple sclerosis patients
- Author
-
Strunk, Tobias, primary, Bubel, Stefanie, additional, Mascher, Beate, additional, Schlenke, Peter, additional, Kirchner, Holger, additional, and Wandinger, Klaus‐Peter, additional
- Published
- 2000
- Full Text
- View/download PDF
120. Method of bacterial killing differentially affects the human innate immune response to Staphylococcus epidermidis.
- Author
-
Strunk, Tobias, Richmond, Peter, Prosser, Amy, Simmer, Karen, Levy, Ofer, Burgner, David, and Currie, Andrew
- Subjects
- *
NATURAL immunity , *IMMUNE response , *STAPHYLOCOCCUS , *MACROPHAGES , *CYTOKINES , *GENE expression , *TRANSCRIPTION factors - Abstract
Background:In vitro investigations of human innate immune responses to extracellular bacteria commonly utilise killed preparations in preference to live organisms. The effects of the bacterial preparation method on the activation of innate signalling pathways by the common opportunistic pathogen Staphylococcus epidermidis (SE) are unknown.Materials and methods: Mononuclear cell cytokine expression patterns induced by live (LSE), heat-killed (HKSE) and ethanol-killed SE (EKSE) were characterized at the transcriptional and translational level. Toll-like receptor (TLR)-activating capacity of the preparations was analysed using TLR-transfected human embryonic kidney cells.Results: Live SE activated NF-κB, STAT1, type I interferon, and inflammasome pathways. Killed preparations engaged the NF-κB pathway, but had significantly lower capacity to activate other innate immune pathways.Conclusions: Killing of extracellular bacteria has significant qualitative and quantitative effects on key aspects of innate responses in vitro. Interpretation of in vitro data and extrapolation of findings should take into account the potential effects of bacterial preparation and should not assume that responses to killed bacteria are predictive of responses to live organisms. [ABSTRACT FROM PUBLISHER]
- Published
- 2011
- Full Text
- View/download PDF
121. Innate immunity in human newborn infants: prematurity means more than immaturity.
- Author
-
Strunk, Tobias, Currie, Andrew, Richmond, Peter, Simmer, Karen, and Burgner, David
- Subjects
- *
NEONATAL infections , *PREMATURE infants , *NATURAL immunity , *PEDIATRIC therapy ,PREMATURE infant death - Abstract
Neonates, particularly those born prematurely, are exquisitely vulnerable to life-threatening infections. This increased susceptibility to infection is maintained into childhood. Despite the considerable human and economic cost of infection-related neonatal morbidity and mortality, the mechanisms underlying this heightened susceptibility are only partly understood. It is increasingly recognised that innate immune responses are key to the protection against infection early in life, and emerging data suggest that such responses are deficient in the newborn and especially in preterm infants. Here we review the current understanding of the maturation of the innate immune response in human neonates highlighting the clinical relevance and possible avenues for therapeutic intervention. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
122. Increased numbers of CCR5+ interferon-γ- and tumor necrosis factor-α-secreting T lymphocytes in multiple sclerosis patients.
- Author
-
Strunk, Tobias, Bubel, Stefanie, Mascher, Beate, Schlenke, Peter, Kirchner, Holger, and Wandinger, Klaus-Peter
- Published
- 2000
- Full Text
- View/download PDF
123. Correction: Neonatal sepsis: need for consensus definition, collaboration and core outcomes.
- Author
-
Molloy, Eleanor J., Wynn, James L., Bliss, Joseph, Koenig, Joyce M., Keij, Fleur M., McGovern, Matt, Kuester, Helmut, Turner, Mark A., Giannoni, Eric, Mazela, Jan, Degtyareva, Marina, Strunk, Tobias, Simons, Sinno H. P., Janota, Jan, Plotz, Franz B., van den Hoogen, Ages, de Boode, Willem, Schlapbach, Luregn J., Reiss, Irwin K. M., and Infection, Inflammation, Immunology and Immunisation (I4) section of the ESPR
- Published
- 2021
- Full Text
- View/download PDF
124. Increased numbers of CCR5+interferon‐γ– and tumor necrosis factor‐α–secreting T lymphocytes in multiple sclerosis patients
- Author
-
Strunk, Tobias, Bubel, Stefanie, Mascher, Beate, Schlenke, Peter, Kirchner, Holger, and Wandinger, Klaus‐Peter
- Abstract
To determine the frequency of in vivo activated TH1 lymphocytes, T‐cell subsets of 9 multiple sclerosis patients with active disease and 17 healthy controls were analyzed by immunostaining for CCR5, CD26, and their expression of interleukin‐2, interferon‐γ, and tumor necrosis factor‐α. The numbers of CCR5+interferon‐γ– and tumor necrosis factor‐α–producing T cells were significantly increased in the peripheral blood of multiple sclerosis patients. CCR5 expression may be a useful marker to identify effector cells in multiple sclerosis and could be used as a tool for monitoring disease activity. Ann Neurol 2000;47:269–273
- Published
- 2000
- Full Text
- View/download PDF
125. Increased numbers of CCR5<SUP>+</SUP> interferon-γ and tumor necrosis factor-αsecreting T lymphocytes in multiple sclerosis patients
- Author
-
Strunk, Tobias, Bubel, Stefanie, Mascher, Beate, Schlenke, Peter, Kirchner, Holger, and Wandinger, Klaus-Peter
- Abstract
To determine the frequency of in vivo activated T
H 1 lymphocytes, T-cell subsets of 9 multiple sclerosis patients with active disease and 17 healthy controls were analyzed by immunostaining for CCR5, CD26, and their expression of interleukin-2, interferon-γ, and tumor necrosis factor-α. The numbers of CCR5+ interferon-γ and tumor necrosis factor-αproducing T cells were significantly increased in the peripheral blood of multiple sclerosis patients. CCR5 expression may be a useful marker to identify effector cells in multiple sclerosis and could be used as a tool for monitoring disease activity. Ann Neurol 2000;47:269273- Published
- 2000
- Full Text
- View/download PDF
126. Effectiveness of Palivizumab against Respiratory Syncytial Virus: Cohort and Case Series Analysis.
- Author
-
Moore, Hannah C., de Klerk, Nicholas, Richmond, Peter C., Fathima, Parveen, Xu, Ruomei, Keil, Anthony D., Snelling, Thomas L., and Strunk, Tobias
- Abstract
To measure the real-world effectiveness of palivizumab immunoprophylaxis against respiratory syncytial virus (RSV)-confirmed infection before age 2 years in a population-cohort of high-risk infants. Palivizumab is funded for high-risk infants in Western Australia. We used probabilistically linked administrative data encompassing RSV laboratory-confirmed infections, hospital admissions, and palivizumab dispensing records for a cohort of 24 329 high-risk infants admitted to neonatal intensive care units, born 2002-2013 with follow-up to 2015. We used a traditional cohort method with Cox proportional hazards regression and a self-controlled case series analysis to assess effectiveness of palivizumab in reducing RSV-confirmed infection by number of doses. From the cohort of 24 329 infants, 271 (1.1%) received at least 1 dose of palivizumab and 1506 (6.2%) had at least 1 RSV-confirmed infection before age 2 years. Using the traditional cohort approach, we found no protective association of palivizumab receipt with RSV detection (adjusted hazard ratio = 0.99 [95% CI 0.5, 1.9] for 1 dose). However, using a self-controlled case series to eliminate confounding by indication, a protective association was seen with a 74% lower RSV incidence (relative incidence = 0.26; 95% CI 0.11, 0.67) following any dose of palivizumab compared with control (nonexposed) periods. After accounting for confounding by indication through a self-controlled analysis, palivizumab appeared effective for reducing virologically confirmed RSV in this high-risk cohort. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
127. Subacute leukencephalopathy after low-dose intrathecal methotrexate in an adolescent heterozygous for the MTHFR C677T polymorphism.
- Author
-
Strunk, Tobias, Gottschalk, Stefan, Goepel, Wolfgang, Bucsky, Peter, and Schultz, Christian
- Published
- 2003
- Full Text
- View/download PDF
128. Growth Parameters, Effect Measure Modification and the Association Between Vaccination and Early Childhood Hospitalization With Non-targeted Infections.
- Author
-
Burgner, David P, Miller, Jessica E, Strunk, Tobias, and Nassar, Natasha
- Subjects
HOSPITAL care ,HUMAN growth ,IMMUNIZATION ,INFECTION - Published
- 2018
- Full Text
- View/download PDF
129. Epidemiology and Outcomes of Neonatal Sepsis: Experience from a Tertiary Australian NICU.
- Author
-
Mackay, Cheryl Anne, Nathan, Elizabeth A., Porter, Michelle Claire, Shrestha, Damber, Kohan, Rolland, and Strunk, Tobias
- Subjects
- *
NEONATAL sepsis , *EPIDEMIOLOGY , *BIRTH weight , *HIGH-income countries , *BRAIN injuries , *SEPSIS - Abstract
Neonatal sepsis is associated with significant mortality and morbidity. Low-middle-income countries are disproportionately affected, but late-onset sepsis (LOS) still occurs in up to 20% of infants <28 weeks in high-income countries. Understanding site-specific data is vital to guide management.Introduction: A retrospective cohort study was conducted at King Edward Memorial Hospital (KEMH), Perth. Infants admitted between January 2012 and June 2022 were included. Data were extracted from routine electronic databases. Incidence and aetiology of sepsis were determined and the association of sepsis with neonatal outcomes analysed.Methods: During the study period, 23,395 newborns were admitted with a median gestation of 37 weeks and birth weight of 2,800 g. There were 370 sepsis episodes in 350 infants; 102 were early-onset sepsis (EOS) (1.6 per 1,000 live births), predominantlyResults: Streptococcus agalactiae (35, 34.3%) andEscherichia coli (27, 26.5%); 268 were LOS (0.9 per 1,000 inpatient days), predominantly coagulase-negative staphylococci (CONS) (156, 57.6%) andE. coli (30, 11.1%). The incidence of LOS declined from 2012 to 2022 (p = 0.002). Infants with EOS had increased brain injury (25.7% vs. 4.1%;p = 0.002) and mortality (18.8% vs. 1.6%;p < 0.001). Those with LOS had increased hospital stay (median 95 vs. 15 days;p < 0.001), mortality (15.3% vs. 1.6%;p = 0.018), necrotising enterocolitis (NEC) (7.4% vs. 0.5%;p < 0.001), and chronic lung disease (CLD) (58.1% vs. 5.9%;p = 0.005). Infants <28 weeks with sepsis were at increased risk of neurodevelopmental impairment compared to those without infection (43.2% vs. 30.9%,p = 0.027). While we observed a reduction in LOS incidence, sepsis remains associated with higher mortality, and in survivors with longer hospital stay and increased risk of brain injury, NEC, CLD, and neurodevelopmental impairment. [ABSTRACT FROM AUTHOR]Conclusions: - Published
- 2024
- Full Text
- View/download PDF
130. Outcomes of interventions in neonatal sepsis: A systematic review of qualitative research.
- Author
-
Taneri, Petek Eylul, Devane, Declan, Kirkham, Jamie, Molloy, Eleanor, Daly, Mandy, Branagan, Aoife, Suguitani, Denise, Wynn, James L., Kissoon, Niranjan, Kawaza, Kondwani, Simons, Sinno H. P., Bonnard, Lívia Nagy, Giannoni, Eric, Strunk, Tobias, Ohaja, Magdalena, Mugabe, Kenneth, Quirke, Fiona, Bazilio, Kateregga, and Biesty, Linda
- Abstract
Background Objectives Search Strategy Selection Criteria Data Collection and Analysis Main Results Conclusions While a systematic review exists detailing neonatal sepsis outcomes from clinical trials, there remains an absence of a qualitative systematic review capturing the perspectives of key stakeholders.Our aim is to identify outcomes from qualitative research on any intervention to prevent or improve the outcomes of neonatal sepsis that are important to parents, other family members, healthcare providers, policymakers, and researchers as a part of the development of a core outcome set (COS) for neonatal sepsis.A literature search was carried out using MEDLINE, EMBASE, CINAHL, and PsycInfo databases.Publications describing qualitative data relating to neonatal sepsis outcomes were included.Drawing on the concepts of thematic synthesis, texts related to outcomes were coded and grouped. These outcomes were then mapped to the domain headings of an existing model.Out of 6777 records screened, six studies were included. Overall, 19 outcomes were extracted from the included studies. The most frequently reported outcomes were those in the domains related to parents, healthcare workers and individual organ systemas such as gastrointestinal system. The remaining outcomes were classified under the headings of general outcomes, miscellaneous outcomes, survival, and infection.The outcomes identified in this review are different from those reported in neonatal sepsis clinical trials, thus highlighting the importance of incorporating qualitative studies into COS development to encapsulate all relevant stakeholders' perspectives. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
131. Angiogenesis-associated pathways play critical roles in neonatal sepsis outcomes.
- Author
-
Fidanza, Mario, Hibbert, Julie, Acton, Erica, Harbeson, Danny, Schoeman, Elizna, Skut, Patrycja, Woodman, Tabitha, Eynaud, Adrien, Hartnell, Lucy, Brook, Byron, Cai, Bing, Lo, Mandy, Falsafi, Reza, Hancock, Robert E. W., Chiume-Kayuni, Msandeni, Lufesi, Norman, Popescu, Constantin R., Lavoie, Pascal M., Strunk, Tobias, and Currie, Andrew J.
- Abstract
Neonatal sepsis is a major cause of childhood mortality. Limited diagnostic tools and mechanistic insights have hampered our abilities to develop prophylactic or therapeutic interventions. Biomarkers in human neonatal sepsis have been repeatedly identified as associated with dysregulation of angiopoietin signaling and altered arachidonic acid metabolism. We here provide the mechanistic evidence in support of the relevance for these observations. Angiopoetin-1 (Ang-1), which promotes vascular integrity, was decreased in blood plasma of human and murine septic newborns. In preclinical models, administration of Ang-1 provided prophylactic protection from septic death. Arachidonic acid metabolism appears to be functionally connected to Ang-1 via reactive oxygen species (ROS) with a direct role of nitric oxide (NO). Strengthening this intersection via oral administration of arachidonic acid and/or the NO donor L-arginine provided prophylactic as well as therapeutic protection from septic death while also increasing plasma Ang-1 levels among septic newborns. Our data highlight that targeting angiogenesis-associated pathways with interventions that increase Ang-1 activity directly or indirectly through ROS/eNOS provide promising avenues to prevent and/or treat severe neonatal sepsis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
132. Protocol for the development of a core outcome set for neonatal sepsis (NESCOS).
- Author
-
Taneri, Petek Eylul, Kirkham, Jamie J., Molloy, Eleanor J., Biesty, Linda, Polin, Richard A., Wynn, James L., Stoll, Barbara J., Kissoon, Niranjan, Kawaza, Kondwani, Daly, Mandy, Branagan, Aoife, Bonnard, Lívia Nagy, Giannoni, Eric, Strunk, Tobias, Ohaja, Magdalena, Mugabe, Kenneth, Suguitani, Denise, Quirke, Fiona, and Devane, Declan
- Subjects
- *
SEPSIS , *NEONATAL sepsis , *MEDICAL personnel , *RESEARCH personnel , *PARENTS , *PUBLIC health - Abstract
Neonatal sepsis is a serious public health problem; however, there is substantial heterogeneity in the outcomes measured and reported in research evaluating the effectiveness of the treatments. Therefore, we aim to develop a Core Outcome Set (COS) for studies evaluating the effectiveness of treatments for neonatal sepsis. Since a systematic review of key outcomes from randomised trials of therapeutic interventions in neonatal sepsis was published recently, we will complement this with a qualitative systematic review of the key outcomes of neonatal sepsis identified by parents, other family members, parent representatives, healthcare providers, policymakers, and researchers. We will interpret the outcomes of both studies using a previously established framework. Stakeholders across three different groups i.e., (1) researchers, (2) healthcare providers, and (3) patients' parents/family members and parent representatives will rate the importance of the outcomes in an online Real-Time Delphi Survey. Afterwards, consensus meetings will be held to agree on the final COS through online discussions with key stakeholders. This COS is expected to minimize outcome heterogeneity in measurements and publications, improve comparability and synthesis, and decrease research waste. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
133. Skin-Microbiome Assembly in Preterm Infants during the First Three Weeks of Life and Impact of Topical Coconut Oil Application.
- Author
-
Ghori, Noor-Ul-Huda, Mullally, Christopher A., Nicol, Mark P., Currie, Andrew, Hibbert, Julie, Payne, Matthew S., Patole, Sanjay, and Strunk, Tobias
- Subjects
- *
PREMATURE infants , *INFANTS , *COCONUT oil , *SKIN care , *INFANT care , *GROIN , *CLINICAL trials , *EAR - Abstract
The structure and function of infant skin is not fully developed until 34 weeks of gestation, and this immaturity is associated with risk of late-onset sepsis (LOS). Topical coconut oil improves preterm-infant skin integrity and may reduce LOS. However, data on early-life skin-microbiome succession and potential effects of emollient skin care in preterm infants are scarce. We therefore collected skin-microbiome samples from the ear, axilla, and groin on days 1, 7, 14, and 21 from preterm infants born <30 weeks of gestation as part of a randomized clinical trial of standard skin care vs. topical coconut oil. We found that within-sample microbiome diversity was highest on day 1 after birth, with a subsequent decline and emergence of Staphylococcus genus dominance from day 7. Moreover, microbiome assembly was less diverse in infants receiving coconut oil vs. standard skin care. Our study provides novel data on preterm-infant skin-microbiome composition and highlights the modifying potential of emollient skin care. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
134. Rhodococcus equiMeningitis After Ventriculoperitoneal Shunt Insertion in a Preterm Infant
- Author
-
Strunk, Tobias, Gardiner, Katharine, Simmer, Karen, Atlas, David, and Keil, Anthony D.
- Published
- 2007
- Full Text
- View/download PDF
135. Intravenous pentoxifylline is well tolerated in critically ill preterm infants with sepsis or necrotizing enterocolitis.
- Author
-
Schüller, Simone S, Kempf, Kristina, Unterasinger, Lukas, Strunk, Tobias, and Berger, Angelika
- Subjects
- *
PREMATURE infants , *NEONATAL necrotizing enterocolitis , *ENTEROCOLITIS , *PENTOXIFYLLINE , *CRITICALLY ill , *SEPSIS - Abstract
Pentoxifylline (PTX) is a candidate adjuvant medication for the treatment of sepsis and necrotizing enterocolitis in preterm infants. There is only limited data on safety and compatibility with other commonly used intravenous medications. This retrospective single-center study of 198 preterm infants (September 2012–September 2018) was performed at a level IV neonatal intensive care unit. Electronic data of all preterm infants who received pentoxifylline for sepsis or necrotizing were extracted from routine databases. We analyzed a total of 1081 PTX treatment days from 217 treatment episodes in 198 preterm infants (mean gestational age 27 weeks; mean birth weight 1060 g). At a mean daily dose of 28 mg/kg, no clinically relevant side effects were observed. PTX therapy was not associated with clinically significant changes of blood biochemistry and hematology parameters. Concomitant infusion of PTX with other common NICU medications was well tolerated, and there was no evidence of incompatibility. Conclusion: Intravenous PTX is compatible with standard NICU drugs and well tolerated in critically ill preterm infants. What is Know: •Currently, there are no evidence-based adjuvant medications available that target the harmful inflammatory host response in neonatal sepsis or necrotizing enterocolitis. •Pentoxifylline (PTX) is a candidate adjuvant medication for the treatment of sepsis and necrotizing enterocolitis in preterm infants; however, safety data are rare and PTX is currently used off-label. What is New: •Here we report on our experience in the pragmatic routine use of PTX as adjuvant therapy in 198 preterm infants with sepsis or NEC. •Concomitant infusion of PTX with other common NICU medications was well tolerated, and there was no evidence of incompatibility. No clinically relevant side effects were observed. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
136. Whole-of-Life Inclusion in Bayesian Adaptive Platform Clinical Trials.
- Author
-
Campbell AJ, Anpalagan K, Best EJ, Britton PN, Gwee A, Hatcher J, Manley BJ, Marsh J, Webb RH, Davis JS, Mahar RK, McGlothlin A, McMullan B, Meyer M, Mora J, Murthy S, Nourse C, Papenburg J, Schwartz KL, Scheuerman O, Snelling T, Strunk T, Stark M, Voss L, Tong SYC, and Bowen AC
- Abstract
Importance: There is a recognized unmet need for clinical trials to provide evidence-informed care for infants, children and adolescents. This Special Communication outlines the capacity of 3 distinct trial design strategies, sequential, parallel, and a unified adult-pediatric bayesian adaptive design, to incorporate children into clinical trials and transform this current state of evidence inequity. A unified adult-pediatric whole-of-life clinical trial is demonstrated through the Staphylococcus aureus Network Adaptive Platform (SNAP) trial., Observations: Bayesian methods provide a framework for synthesizing data in the form of a probability model that can be used in the design and analysis of a clinical trial. Three trial design strategies are compared: (1) a sequential adult-pediatric bayesian approach that involves a separate, deferred pediatric trial that incorporates existing adult trial data into the analysis model to potentially reduce the pediatric trial sample size; (2) a parallel adult-pediatric bayesian trial whereby separate pediatric enrollment occurs in a parallel trial, running alongside an adult randomized clinical trial; and (3) a unified adult-pediatric bayesian adaptive design that supports the enrollment of both children and adults simultaneously in a whole-of-life bayesian adaptive randomized clinical trial. The SNAP trial whole-of-life design uses a bayesian hierarchical model that allows information sharing (also known as borrowing) between trial age groups by linking intervention effects of children and adults, thereby improving inference in both groups., Conclusion and Relevance: Bayesian hierarchical models may provide more precision for estimates of safety and efficacy of treatments in trials with heterogenous populations compared to traditional methods of analysis. They facilitate the inclusion of children in clinical trials and a shift from children deemed therapeutic orphans to the vision of no child left behind in clinical trials to ensure evidence for clinical practice exists across the life course. The SNAP trial provides an example of a bayesian adaptive whole-of-life inclusion design that enhances trial population inclusivity and diversity overall, as well as generalizability and translation of findings into clinical practice.
- Published
- 2024
- Full Text
- View/download PDF
137. Correction: Neonatal sepsis definitions from randomised clinical trials.
- Author
-
Hayes R, Hartnett J, Semova G, Murray C, Murphy K, Carroll L, Plapp H, Hession L, O'Toole J, McCollum D, Roche E, Jenkins E, Mockler D, Hurley T, McGovern M, Allen J, Meehan J, Plötz FB, Strunk T, de Boode WP, Polin R, Wynn JL, Degtyareva M, Küster H, Janota J, Giannoni E, Schlapbach LJ, Keij FM, Reiss IKM, Bliss J, Koenig JM, Turner MA, Gale C, and Molloy EJ
- Published
- 2024
- Full Text
- View/download PDF
138. Neonatal bacterial sepsis.
- Author
-
Strunk T, Molloy EJ, Mishra A, and Bhutta ZA
- Subjects
- Humans, Infant, Newborn, Neonatal Sepsis diagnosis, Neonatal Sepsis therapy, Anti-Bacterial Agents therapeutic use
- Abstract
Neonatal sepsis remains one of the key challenges of neonatal medicine, and together with preterm birth, causes almost 50% of all deaths globally for children younger than 5 years. Compared with advances achieved for other serious neonatal and early childhood conditions globally, progress in reducing neonatal sepsis has been much slower, especially in low-resource settings that have the highest burden of neonatal sepsis morbidity and mortality. By contrast to sepsis in older patients, there is no universally accepted neonatal sepsis definition. This poses substantial challenges in clinical practice, research, and health-care management, and has direct practical implications, such as diagnostic inconsistency, heterogeneous data collection and surveillance, and inappropriate treatment, health-resource allocation, and education. As the clinical manifestation of neonatal sepsis is frequently non-specific and the current diagnostic standard blood culture has performance limitations, new improved diagnostic techniques are required to guide appropriate and warranted antimicrobial treatment. Although antimicrobial therapy and supportive care continue as principal components of neonatal sepsis therapy, refining basic neonatal care to prevent sepsis through education and quality improvement initiatives remains paramount., Competing Interests: Declaration of interests We declare no competing interests., (Crown Copyright © 2024 Published by Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.)
- Published
- 2024
- Full Text
- View/download PDF
139. Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings.
- Author
-
De Silva DTN, Petrovski M, Strunk T, Mukadam N, Page-Sharp M, Moore BR, and Batty KT
- Subjects
- Humans, Infant, Newborn, Intensive Care, Neonatal, Intensive Care Units, Neonatal, Acyclovir administration & dosage, Acyclovir chemistry, Caffeine chemistry, Caffeine administration & dosage, Citrates chemistry, Citrates administration & dosage, Drug Incompatibility
- Abstract
Purpose: To investigate the physicochemical compatibility of caffeine citrate and caffeine base injections with 43 secondary intravenous (IV) drugs used in Neonatal Intensive Care Unit (NICU) settings., Methods: Caffeine citrate (20 mg/mL or 10 mg/mL) or caffeine base injection (10 mg/mL) were mixed in a volume ratio of 1:1 with the secondary drug solution to simulate Y-site co-administration procedures in NICUs. Physical compatibility was evaluated based on visual observation for 2 h, against a black and white background and under polarised light, for changes in colour, precipitation, haze and evolution of gas. Chemical compatibility was determined from caffeine concentration measurements, using a validated high-performance liquid chromatography assay., Results: Six of the 43 secondary drugs tested (aciclovir, amphotericin (liposomal), furosemide, hydrocortisone, ibuprofen and ibuprofen lysine) were physically incompatible with caffeine citrate undiluted injection (20 mg/mL), at their high-end, clinically relevant concentrations for NICU settings. However, when tested at lower concentrations, hydrocortisone (1 mg/mL) was physicochemically compatible, whereas furosemide (0.2 mg/mL) was physically incompatible with caffeine citrate. The six drugs which showed physical incompatibility with caffeine citrate 20 mg/mL injection were also physically incompatible with caffeine citrate 10 mg/mL solution. All 43 secondary drugs tested were physicochemically compatible with caffeine base injection., Conclusions: Most secondary test drugs, except aciclovir, amphotericin (liposomal), furosemide, hydrocortisone, ibuprofen and ibuprofen lysine, were physicochemically compatible with caffeine citrate injection. Caffeine base injection was physicochemically compatible with all 43 test drugs tested., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
140. The Physicochemical Compatibility of Sildenafil Injection with Parenteral Medications Used in Neonatal Intensive Care Settings.
- Author
-
De Silva DTN, Strunk T, Petrovski M, Page-Sharp M, Moore BR, and Batty KT
- Abstract
Sildenafil is used to treat pulmonary hypertension in neonatal intensive care unit (NICU) settings. As multiple intravenous (IV) medications are co-administered in NICU settings, we sought to investigate the physicochemical compatibility of sildenafil with a range of IV drugs. Sildenafil 600 mcg/mL or 60 mcg/mL was mixed 1:1 with the secondary drug solution to simulate Y-site co-administration procedures. Physical compatibility was evaluated by visual observation against a black and white background and under polarized light for two hours for changes in colour, precipitation, haze and evolution of gas. Chemical compatibility was determined from sildenafil concentrations, using a validated, stability-indicating high-performance liquid chromatography assay. Sildenafil 600 mcg/mL was physicochemically compatible with 29 of the 45 drugs tested at 'high-end' clinical concentrations and physically incompatible with 16 drugs and six '2-in-1' parenteral nutrition solutions. Sildenafil 600 mcg/mL was compatible with lower, clinically relevant concentrations of calcium gluconate, heparin and hydrocortisone. Aciclovir, amoxicillin, ampicillin, ibuprofen lysine, indometacin, phenobarbitone and rifampicin were incompatible with sildenafil 600 mcg/mL, however these IV medications were compatible with sildenafil 60 mcg/mL. Sildenafil 600 mcg/mL and 60 mcg/mL were incompatible with amphotericin, flucloxacillin, furosemide, ibuprofen, meropenem and sodium bicarbonate. Sildenafil compatibility with commonly used syringe filters was also investigated. Sildenafil solution was compatible with nylon syringe filters, however, absorption/adsorption loss occurred with polyethersulfone and cellulose ester filters.
- Published
- 2024
- Full Text
- View/download PDF
141. Development of a pharmaceutical science systematic review process using a semi-automated machine learning tool: Intravenous drug compatibility in the neonatal intensive care setting.
- Author
-
De Silva DTN, Moore BR, Strunk T, Petrovski M, Varis V, Chai K, Ng L, and Batty KT
- Subjects
- Humans, Infant, Newborn, Reproducibility of Results, Intensive Care, Neonatal, Machine Learning, Systematic Reviews as Topic
- Abstract
Our objective was to establish and test a machine learning-based screening process that would be applicable to systematic reviews in pharmaceutical sciences. We used the SPIDER (Sample, Phenomenon of Interest, Design, Evaluation, Research type) model, a broad search strategy, and a machine learning tool (Research Screener) to identify relevant references related to y-site compatibility of 95 intravenous drugs used in neonatal intensive care settings. Two independent reviewers conducted pilot studies, including manual screening and evaluation of Research Screener, and used the kappa-coefficient for inter-reviewer reliability. After initial deduplication of the search strategy results, 27 597 references were available for screening. Research Screener excluded 1735 references, including 451 duplicate titles and 1269 reports with no abstract/title, which were manually screened. The remainder (25 862) were subject to the machine learning screening process. All eligible articles for the systematic review were extracted from <10% of the references available for screening. Moderate inter-reviewer reliability was achieved, with kappa-coefficient ≥0.75. Overall, 324 references were subject to full-text reading and 118 were deemed relevant for the systematic review. Our study showed that a broad search strategy to optimize the literature captured for systematic reviews can be efficiently screened by the semi-automated machine learning tool, Research Screener., (© 2024 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
142. Neonatal early-onset sepsis calculator: Impact on antibiotic use in a level II neonatal unit in Western Australia.
- Author
-
Gannon J, Strunk T, Friesen N, and Saw C
- Subjects
- Infant, Newborn, Infant, Pregnancy, Female, Humans, Anti-Bacterial Agents therapeutic use, Western Australia, Retrospective Studies, Risk Assessment, Neonatal Sepsis drug therapy, Neonatal Sepsis epidemiology, Sepsis drug therapy, Sepsis epidemiology
- Abstract
Background: Overuse of empirical intravenous antibiotics in neonates in high-income countries (HICs) is well documented. The Kaiser Permanente neonatal early-onset sepsis (EOS) calculator is an evidence-based sepsis risk assessment tool that has demonstrated potential to reduce antibiotic usage in this population. The incidence of early-onset sepsis in most HICs is 0.4-0.8 per 1000 live births. The objective was to evaluate the calculator's impact on antibiotic rates and length of stay in a regional level II Special Care Nursery., Methods: A single-centre retrospective cohort study compared antibiotic administration rates in the first 72 h in neonates ≥35 weeks gestation born during two 6-month periods in 2019 (pre-EOS calculator) and 2021 (post-EOS calculator). Electronic and paper case records were accessed to capture data. Continuous data were summarised using mean and standard deviation, and categorical data were summarized using frequency distributions. There were 951 (2019) and 1129 (2021) infants born during the study periods., Results: Following implementation of the calculator, antibiotic exposure decreased from 13.7% to 4.7% of all neonates without reported negative outcomes. Mean length of stay for neonates born across the two periods decreased from 2.38 to 2.13 days. Indications for antibiotic use shifted more towards clinical condition and away from obstetric risk factors. There were no culture-proven cases of sepsis or readmissions with EOS in either period., Conclusion: Implementation of the EOS calculator significantly reduced exposure to antibiotics, without adverse outcomes., Competing Interests: Declaration of competing interest The authors have no conflicts of interest relevant to this article and no funding was received for conducting this study., (Copyright © 2023 Taiwan Pediatric Association. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
143. Physical compatibility of lipid emulsions and intravenous medications used in neonatal intensive care settings.
- Author
-
Senarathna SMDKG, Strunk T, Petrovski M, Woodland S, Martinez J, Chuang VTG, and Batty KT
- Abstract
Objective: The purpose of this study was to investigate the physical compatibility of intravenous lipid emulsions with parenteral medications used in neonatal intensive care., Methods: Lipid emulsion and drug solutions were combined 1:1 in glass vials, inspected for physical incompatibility at 0, 1 and 2 hours, and assessed on the basis of lipid droplet size at 0 and 2 hours after mixing. Intravenous fluid controls (Water for Injection, sodium chloride 0.9% w/v, glucose 5% w/v), positive controls (gentamicin, albumin), negative controls (metronidazole, paracetamol, vancomycin) and 21 previously untested drug combinations were evaluated., Results: No phase separation, change in colour, gas production or other visible anomaly was observed. The between-run mean droplet diameter (MDD) for SMOFlipid20% alone (0.301±0.008 µm) was comparable to the lipid emulsion/intravenous fluid and lipid emulsion/drug solution combinations. In addition to gentamicin and albumin, caffeine citrate (20 mg/mL) was shown to be incompatible with the lipid emulsion. All other lipid:drug combinations were compatible, based on the MDD data., Conclusion: Intravenous lipid emulsions were found to be compatible with 20 parenteral medications, including antimicrobial agents, inotropes, anti-inflammatory drugs and caffeine base, in simulated Y-site conditions. The lipid emulsion was incompatible with caffeine citrate injection., Competing Interests: Competing interests: None declared., (© European Association of Hospital Pharmacists 2023. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
144. Physicochemical compatibility of pentoxifylline injection with high-concentration parenteral medications.
- Author
-
Senarathna SMDKG, Strunk T, Petrovski M, Woodland S, and Batty KT
- Abstract
Competing Interests: The authors declare no conflict of interest.
- Published
- 2023
- Full Text
- View/download PDF
145. Health service utilisation for acute respiratory infections in infants graduating from the neonatal intensive care unit: a population-based cohort study.
- Author
-
Stevenson PG, Cooper MN, Billingham W, de Klerk N, Simpson SJ, Strunk T, and Moore HC
- Subjects
- Infant, Newborn, Humans, Child, Preschool, Infant, Cohort Studies, Patient Discharge, Infant, Extremely Premature, Intensive Care Units, Neonatal, Intensive Care, Neonatal
- Abstract
Background: Despite advances in neonatal intensive care, babies admitted to Neonatal Intensive Care Units (NICU) suffer from adverse outcomes. We aim to describe the longer-term respiratory infectious morbidity of infants discharged from NICU using state-wide population-based linked data in Western Australia., Study Design: We used probabilistically linked population-based administrative data to analyse respiratory infection morbidity in a cohort of 23,784 infants admitted to the sole tertiary NICU, born 2002-2013 with follow up to 2015. We analysed incidence rates of secondary care episodes (emergency department presentations and hospitalisations) by acute respiratory infection (ARI) diagnosis, age, gestational age and presence of chronic lung disease (CLD). Poisson regression was used to investigate the differences in rates of ARI hospital admission between gestational age groups and those with CLD, after adjusting for age at hospital admission., Results: From 177,367 child-years at risk (i.e., time that a child could experience an ARI outcome), the overall ARI hospitalisation rate for infants and children aged 0-8 years was 71.4/1000 (95% confidence interval, CI: 70.1, 72.6), with the highest rates in infants aged 0-5 months (242.9/1000). For ARI presentations to emergency departments, equivalent rates were 114/1000 (95% CI: 112.4, 115.5) and 337.6/1000, respectively. Bronchiolitis was the most common diagnosis among both types of secondary care, followed by upper respiratory tract infections. Extremely preterm infants (< 28 weeks gestation at birth) were 6.5 (95% CI: 6.0, 7.0) times more likely and those with CLD were 5.0 (95% CI: 4.7, 5.4) times more likely to be subsequently admitted for ARI than those in NICU who were not preterm or had CLD after adjusting for age at hospital admission., Conclusions: There is an ongoing burden of ARI in children who graduate from the NICU, especially those born extremely preterm, that persists into early childhood. Early life interventions to prevent respiratory infections in these children and understanding the lifelong impact of early ARI on later lung health are urgent priorities., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
146. Less is more: Antibiotics at the beginning of life.
- Author
-
Stocker M, Klingenberg C, Navér L, Nordberg V, Berardi A, El Helou S, Fusch G, Bliss JM, Lehnick D, Dimopoulou V, Guerina N, Seliga-Siwecka J, Maton P, Lagae D, Mari J, Janota J, Agyeman PKA, Pfister R, Latorre G, Maffei G, Laforgia N, Mózes E, Størdal K, Strunk T, and Giannoni E
- Subjects
- Infant, Newborn, Humans, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Beginning of Human Life, Sepsis drug therapy, Neonatal Sepsis drug therapy, Antimicrobial Stewardship
- Abstract
Antibiotic exposure at the beginning of life can lead to increased antimicrobial resistance and perturbations of the developing microbiome. Early-life microbiome disruption increases the risks of developing chronic diseases later in life. Fear of missing evolving neonatal sepsis is the key driver for antibiotic overtreatment early in life. Bias (a systemic deviation towards overtreatment) and noise (a random scatter) affect the decision-making process. In this perspective, we advocate for a factual approach quantifying the burden of treatment in relation to the burden of disease balancing antimicrobial stewardship and effective sepsis management., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
147. Neonatal sepsis definitions from randomised clinical trials.
- Author
-
Hayes R, Hartnett J, Semova G, Murray C, Murphy K, Carroll L, Plapp H, Hession L, O'Toole J, McCollum D, Roche E, Jenkins E, Mockler D, Hurley T, McGovern M, Allen J, Meehan J, Plötz FB, Strunk T, de Boode WP, Polin R, Wynn JL, Degtyareva M, Küster H, Janota J, Giannoni E, Schlapbach LJ, Keij FM, Reiss IKM, Bliss J, Koenig JM, Turner MA, Gale C, and Molloy EJ
- Subjects
- Adult, Child, Humans, Infant, Infant, Newborn, Infant Mortality, Randomized Controlled Trials as Topic, Sepsis diagnosis, Sepsis therapy, Neonatal Sepsis diagnosis
- Abstract
Introduction: Neonatal sepsis is a leading cause of infant mortality worldwide with non-specific and varied presentation. We aimed to catalogue the current definitions of neonatal sepsis in published randomised controlled trials (RCTs)., Method: A systematic search of the Embase and Cochrane databases was performed for RCTs which explicitly stated a definition for neonatal sepsis. Definitions were sub-divided into five primary criteria for infection (culture, laboratory findings, clinical signs, radiological evidence and risk factors) and stratified by qualifiers (early/late-onset and likelihood of sepsis)., Results: Of 668 papers screened, 80 RCTs were included and 128 individual definitions identified. The single most common definition was neonatal sepsis defined by blood culture alone (n = 35), followed by culture and clinical signs (n = 29), and then laboratory tests/clinical signs (n = 25). Blood culture featured in 83 definitions, laboratory testing featured in 48 definitions while clinical signs and radiology featured in 80 and 8 definitions, respectively., Discussion: A diverse range of definitions of neonatal sepsis are used and based on microbiological culture, laboratory tests and clinical signs in contrast to adult and paediatric sepsis which use organ dysfunction. An international consensus-based definition of neonatal sepsis could allow meta-analysis and translate results to improve outcomes., (© 2021. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
148. Analysis of Antibiotic Exposure and Early-Onset Neonatal Sepsis in Europe, North America, and Australia.
- Author
-
Giannoni E, Dimopoulou V, Klingenberg C, Navér L, Nordberg V, Berardi A, El Helou S, Fusch G, Bliss JM, Lehnick D, Guerina N, Seliga-Siwecka J, Maton P, Lagae D, Mari J, Janota J, Agyeman PKA, Pfister R, Latorre G, Maffei G, Laforgia N, Mózes E, Størdal K, Strunk T, and Stocker M
- Subjects
- Infant, Newborn, Infant, Male, Humans, Anti-Bacterial Agents therapeutic use, Retrospective Studies, Cross-Sectional Studies, Australia, North America epidemiology, Neonatal Sepsis drug therapy, Neonatal Sepsis epidemiology
- Abstract
Importance: Appropriate use of antibiotics is life-saving in neonatal early-onset sepsis (EOS), but overuse of antibiotics is associated with antimicrobial resistance and long-term adverse outcomes. Large international studies quantifying early-life antibiotic exposure along with EOS incidence are needed to provide a basis for future interventions aimed at safely reducing neonatal antibiotic exposure., Objective: To compare early postnatal exposure to antibiotics, incidence of EOS, and mortality among different networks in high-income countries., Design, Setting, and Participants: This is a retrospective, cross-sectional study of late-preterm and full-term neonates born between January 1, 2014, and December 31, 2018, in 13 hospital-based or population-based networks from 11 countries in Europe and North America and Australia. The study included all infants born alive at a gestational age greater than or equal to 34 weeks in the participating networks. Data were analyzed from October 2021 to March 2022., Exposures: Exposure to antibiotics started in the first postnatal week., Main Outcomes and Measures: The main outcomes were the proportion of late-preterm and full-term neonates receiving intravenous antibiotics, the duration of antibiotic treatment, the incidence of culture-proven EOS, and all-cause and EOS-associated mortality., Results: A total of 757 979 late-preterm and full-term neonates were born in the participating networks during the study period; 21 703 neonates (2.86%; 95% CI, 2.83%-2.90%), including 12 886 boys (59.4%) with a median (IQR) gestational age of 39 (36-40) weeks and median (IQR) birth weight of 3250 (2750-3750) g, received intravenous antibiotics during the first postnatal week. The proportion of neonates started on antibiotics ranged from 1.18% to 12.45% among networks. The median (IQR) duration of treatment was 9 (7-14) days for neonates with EOS and 4 (3-6) days for those without EOS. This led to an antibiotic exposure of 135 days per 1000 live births (range across networks, 54-491 days per 1000 live births). The incidence of EOS was 0.49 cases per 1000 live births (range, 0.18-1.45 cases per 1000 live births). EOS-associated mortality was 3.20% (12 of 375 neonates; range, 0.00%-12.00%). For each case of EOS, 58 neonates were started on antibiotics and 273 antibiotic days were administered., Conclusions and Relevance: The findings of this study suggest that antibiotic exposure during the first postnatal week is disproportionate compared with the burden of EOS and that there are wide (up to 9-fold) variations internationally. This study defined a set of indicators reporting on both dimensions to facilitate benchmarking and future interventions aimed at safely reducing antibiotic exposure in early life.
- Published
- 2022
- Full Text
- View/download PDF
149. Neonatal Staphylococcus Aureus Sepsis: a 20-year Western Australian experience.
- Author
-
Shadbolt R, We MLS, Kohan R, Porter M, Athalye-Jape G, Nathan E, Shrestha D, and Strunk T
- Subjects
- Infant, Newborn, Infant, Child, Humans, Staphylococcus aureus, Retrospective Studies, Australia, Intensive Care Units, Neonatal, Staphylococcal Infections epidemiology, Bacteremia, Sepsis epidemiology
- Abstract
Objectives: The purpose of this study was to characterise neonatal Staphylococcus aureus (SA) sepsis in Western Australia (WA) between 2001 and 2020 at the sole tertiary neonatal intensive care unit (NICU), examine risk factors for sepsis in the cohort, and compare short- and long-term outcomes to control infants without any sepsis., Methods: Retrospective cohort study at the Neonatal Directorate at King Edward Memorial Hospital (KEMH) and Perth Children's Hospital, using electronic databases and patient medical records., Results: The overall incidence of SA sepsis was 0.10 per 1000 live births (62/614207). From 2001 to 2010 the incidence was 0.13/1000 live births, reducing to 0.07/1000 live births from 2011 to 2020. SA was most frequently isolated from endotracheal aspirates, and infants with SA sepsis had longer median duration of ventilatory support than those without any sepsis (31 days vs 18 days respectively, p < 0.001). In our cohort, SA sepsis was associated with worse neurodevelopmental outcomes compared to infants without any sepsis., Conclusions: The incidence of neonatal SA sepsis has reduced over the last 20 years, suggesting potential effectiveness of the preventative interventions implemented. Endotracheal tube (ETT) colonisation and prolonged ventilation may be under-recognised as potential sources of SA infection. Our study suggests SA sepsis may negatively impact neurodevelopmental outcomes., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
150. Neonatal sepsis: a systematic review of core outcomes from randomised clinical trials.
- Author
-
Henry CJ, Semova G, Barnes E, Cotter I, Devers T, Rafaee A, Slavescu A, Cathain NO, McCollum D, Roche E, Mockler D, Allen J, Meehan J, Klingenberg C, Latour JM, van den Hoogen A, Strunk T, Giannoni E, Schlapbach LJ, Degtyareva M, Plötz FB, de Boode WP, Naver L, Wynn JL, Küster H, Janota J, Keij FM, Reiss IKM, Bliss JM, Polin R, Koenig JM, Turner MA, Gale C, and Molloy EJ
- Subjects
- Delphi Technique, Humans, Infant, Newborn, Outcome Assessment, Health Care, Randomized Controlled Trials as Topic, Treatment Outcome, Neonatal Sepsis diagnosis, Neonatal Sepsis therapy, Research Design
- Abstract
Background: The lack of a consensus definition of neonatal sepsis and a core outcome set (COS) proves a substantial impediment to research that influences policy and practice relevant to key stakeholders, patients and parents., Methods: A systematic review of the literature was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. In the included studies, the described outcomes were extracted in accordance with the provisions of the Core Outcome Measures in Effectiveness Trials (COMET) handbook and registered., Results: Among 884 abstracts identified, 90 randomised controlled trials (RCTs) were included in this review. Only 30 manuscripts explicitly stated the primary and/or secondary outcomes. A total of 88 distinct outcomes were recorded across all 90 studies included. These were then assigned to seven different domains in line with the taxonomy for classification proposed by the COMET initiative. The most frequently reported outcome was survival with 74% (n = 67) of the studies reporting an outcome within this domain., Conclusions: This systematic review constitutes one of the initial phases in the protocol for developing a COS in neonatal sepsis. The paucity of standardised outcome reporting in neonatal sepsis hinders comparison and synthesis of data. The final phase will involve a Delphi Survey to generate a COS in neonatal sepsis by consensus recommendation., Impact: This systematic review identified a wide variation of outcomes reported among published RCTs on the management of neonatal sepsis. The paucity of standardised outcome reporting hinders comparison and synthesis of data and future meta-analyses with conclusive recommendations on the management of neonatal sepsis are unlikely. The final phase will involve a Delphi Survey to determine a COS by consensus recommendation with input from all relevant stakeholders., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.